Menu Search
Equities

Clinuvel Pharmaceuticals Ltd

UR9:MUN

Clinuvel Pharmaceuticals Ltd

Actions
  • Price (EUR)8.36
  • Today's Change0.01 / 0.12%
  • Shares traded469.00
  • 1 Year change-11.08%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024 07:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

  • Revenue in AUD (TTM)95.50m
  • Net income in AUD35.64m
  • Incorporated1999
  • Employees16.00
  • Location
    Clinuvel Pharmaceuticals LtdLevel 22, 535 Bourke StreetMELBOURNE 3000AustraliaAUS
  • Phone+61 39660-4900
  • Fax+61 39660-4909
  • Websitehttps://www.clinuvel.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.